These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 28000536)

  • 1. Immune checkpoint inhibitors renal side effects and management.
    Rassy EE; Kourie HR; Rizkallah J; Karak FE; Hanna C; Chelala DN; Ghosn M
    Immunotherapy; 2016 Dec; 8(12):1417-1425. PubMed ID: 28000536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dermatologic adverse events of checkpoint inhibitors: what an oncologist should know.
    Habre M; Habre SB; Kourie HR
    Immunotherapy; 2016 Dec; 8(12):1437-1446. PubMed ID: 28000535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review.
    Wanchoo R; Karam S; Uppal NN; Barta VS; Deray G; Devoe C; Launay-Vacher V; Jhaveri KD;
    Am J Nephrol; 2017; 45(2):160-169. PubMed ID: 28076863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoint inhibitors side effects and management.
    Kourie HR; Klastersky J
    Immunotherapy; 2016 Jun; 8(7):799-807. PubMed ID: 27349979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New NCCN Guidelines: Recognition and Management of Immunotherapy-Related Toxicity.
    Thompson JA
    J Natl Compr Canc Netw; 2018 May; 16(5S):594-596. PubMed ID: 29784734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune Checkpoint Inhibitor-Induced Colitis: Diagnosis and Management.
    Prieux-Klotz C; Dior M; Damotte D; Dreanic J; Brieau B; Brezault C; Abitbol V; Chaussade S; Coriat R
    Target Oncol; 2017 Jun; 12(3):301-308. PubMed ID: 28540478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors.
    Terranova-Barberio M; Thomas S; Munster PN
    Immunotherapy; 2016 Jun; 8(6):705-19. PubMed ID: 27197539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adapting Cancer Immunotherapy Models for the Real World.
    Klevorn LE; Teague RM
    Trends Immunol; 2016 Jun; 37(6):354-363. PubMed ID: 27105824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endocrine side effects induced by immune checkpoint inhibitors.
    Corsello SM; Barnabei A; Marchetti P; De Vecchis L; Salvatori R; Torino F
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1361-75. PubMed ID: 23471977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opportunistic autoimmunity secondary to cancer immunotherapy (OASI): An emerging challenge.
    Kostine M; Chiche L; Lazaro E; Halfon P; Charpin C; Arniaud D; Retornaz F; Blanco P; Jourde-Chiche N; Richez C; Stavris C
    Rev Med Interne; 2017 Aug; 38(8):513-525. PubMed ID: 28214182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update.
    Nagai H; Muto M
    Int J Clin Oncol; 2018 Jun; 23(3):410-420. PubMed ID: 29516216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute and Long-term Adverse Events Associated With Checkpoint Blockade.
    Davies M
    Semin Oncol Nurs; 2019 Oct; 35(5):150926. PubMed ID: 31514992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autoimmune Cardiotoxicity of Cancer Immunotherapy.
    Cheng F; Loscalzo J
    Trends Immunol; 2017 Feb; 38(2):77-78. PubMed ID: 27919707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors.
    Pitt JM; Vétizou M; Daillère R; Roberti MP; Yamazaki T; Routy B; Lepage P; Boneca IG; Chamaillard M; Kroemer G; Zitvogel L
    Immunity; 2016 Jun; 44(6):1255-69. PubMed ID: 27332730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune-related adverse events with immune checkpoint blockade: a comprehensive review.
    Michot JM; Bigenwald C; Champiat S; Collins M; Carbonnel F; Postel-Vinay S; Berdelou A; Varga A; Bahleda R; Hollebecque A; Massard C; Fuerea A; Ribrag V; Gazzah A; Armand JP; Amellal N; Angevin E; Noel N; Boutros C; Mateus C; Robert C; Soria JC; Marabelle A; Lambotte O
    Eur J Cancer; 2016 Feb; 54():139-148. PubMed ID: 26765102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicity patterns associated with chemotherapy/immune checkpoint inhibitor combinations: a meta-analysis.
    Abdel-Rahman O
    Immunotherapy; 2019 Apr; 11(6):543-554. PubMed ID: 31135244
    [No Abstract]   [Full Text] [Related]  

  • 17. [Therapy monitoring and management of adverse events in PD-1/PD-L1 immune checkpoint inhibition].
    Oppel-Heuchel H; Grimm MO
    Urologe A; 2016 May; 55(5):677-90. PubMed ID: 27146870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy of advanced renal cell carcinoma: Current and future therapies.
    Gill D; Hahn AW; Sonpavde G; Agarwal N
    Hum Vaccin Immunother; 2016 Dec; 12(12):2997-3004. PubMed ID: 27494417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?
    Denis M; Duruisseaux M; Brevet M; Dumontet C
    Front Immunol; 2020; 11():492. PubMed ID: 32265935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and Management of Immune-Related Adverse Events in Patients Undergoing Treatment with Immune Checkpoint Inhibitors.
    Kottschade LA
    Curr Oncol Rep; 2018 Mar; 20(3):24. PubMed ID: 29511902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.